Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04385-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Runze Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Surgery Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Immunotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, with 70-80% of patients presenting advanced/metastatic disease. Conventional first-line chemotherapies have limitations, and targeted-immunotherapy combinations need real-world validation. This retrospective, single-center case series enrolled 12 advanced ICC patients to describe the real-world clinical characteristics, treatment patterns which including lenvatinib-based targeted-immunotherapy with or without Transarterial Interventional Therapies (TAIT) and conventional chemotherapy, as well as early efficacy and safety outcomes; and to generate preliminary hypotheses for subsequent prospective studies, without any intention to compare the efficacy of different regimens. Among the 12 patients, objective response rate was 33.3%, and disease control rate 83.33%. Nine received lenvatinib + PD-1/PD-L1 inhibitors (targeted-immunotherapy group), and 3 received systemic chemotherapy. Among patients receiving lenvatinib + PD-1/PD-L1 inhibitors, 22.22% experienced grade ≥ 3 treatment-related adverse events (TRAEs) with a median treatment duration of 9.0 months; among patients receiving conventional chemotherapy, 66.7% experienced grade ≥ 3 TRAEs with a median treatment duration of 19.0 months. Early TAIT (≤ 2 weeks) was associated with higher tumor reduction (mean 30.52 vs. 7.69% for non-early), which may help alleviate tumor-related symptoms in patients with high initial tumor burden. Baseline CA19-9 and albumin/globulin ratio showed exploratory potential associations with treatment efficacy without formal statistical analysis; larger initial diameter correlated with better response. This study describes that lenvatinib + Immune Checkpoint Inhibitors (ICIs) combined with early TAIT may be a feasible multimodal strategy used in real-world practice for advanced ICC, with preliminary observations of feasibility. Limitations include small single-center sample and short follow-up. The high heterogeneity of treatment regimens may also limit the comparability of efficacy and safety. Larger prospective studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatobiliary Surgery Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China.
- Interventional Therapy Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China. beijing712712@163.com.
Zitieren
APA
Yu, R., Zhao, H., & Yan, D. (2026). Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04385-0
Vancouver
Yu R, Zhao H, Yan D. Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04385-0
BibTeX
@article{Yu2026,
author = {Yu, Runze and Zhao, Hong and Yan, Dong},
title = {Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04385-0}
}
EUVIMED